NCT00756743

Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers

A Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04802540 After Multiple Oral Dose Administration To Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 21 Years – 54 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to healthy adult subjects.

Detailed description

Evaluation of safety and pharmacokinetics

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PF-04802540	Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
DRUG	Placebo	Placebo capsules q12 hours for 10 days

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2008-09-22
• Last updated: 2010-03-19

Locations

1 site across 1 country: Singapore